{"id":62948,"date":"2026-04-16T10:02:25","date_gmt":"2026-04-16T08:02:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/"},"modified":"2026-04-16T10:02:25","modified_gmt":"2026-04-16T08:02:25","slug":"integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/","title":{"rendered":"Integrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO"},"content":{"rendered":"
\n

SYDNEY–(BUSINESS WIRE)–#ArtificialIntelligence<\/a>–Integrant, a pioneering Australian biotechnology company, proudly announced today that it has officially been granted the Nasdaq ticker symbol **INGT**. This milestone facilitates the company\u2019s highly anticipated Initial Public Offering (IPO) on the Nasdaq Stock Market, positioning Integrant as a global leader in AI-enhanced regenerative medicine.<\/p>\n

<\/a>
<\/a><\/p>\n

\nEstablished in Sydney, Integrant specialises in the seamless integration of regenerative medical therapies with orthopaedic applications. Founded in 2015, the company has developed a world-class portfolio of innovative solutions for bone healing, fracture management, and cartilage regeneration. Its flagship intra-articular injection therapy targets meniscus cartilage repair, offering a non-invasive, disease-modifying treatment for osteoarthritis that could transform the $15 billion+ global market and reduce the need for knee replacement surgery.<\/p>\n

\nWhat sets Integrant apart is its innate AI capability. The company\u2019s proprietary AI platforms harness machine learning to accelerate biomaterial design, optimise patient-specific regenerative protocols, and predict clinical outcomes with unprecedented precision. This fusion of artificial intelligence and regenerative science enables faster development cycles, personalised therapies, and superior efficacy in orthopaedic applications spanning foot and ankle, spine, knee, and beyond.<\/p>\n

\n\u201cThe granting of our Nasdaq ticker symbol INGT is a powerful validation of our vision to revolutionise regenerative medicine through AI innovation,\u201d said Sam Kalaliya, Wassup Artificial Intelligence Lead at Integrant. \u201cThis IPO will accelerate our clinical programs, expand global commercialisation, and deliver transformative treatments to patients worldwide. Australian ingenuity meets cutting-edge technology \u2014 we are thrilled to bring this future to the public markets.\u201d<\/p>\n

\nThe IPO proceeds will fund advanced clinical trials, regulatory submissions, and international market entry, building on Integrant\u2019s established Australian footprint and growing international partnerships.<\/p>\n

\nIntegrant\u2019s products, including frame IT and advanced biologic processing systems, are already gaining traction in the Asia-Pacific region. With AI at its core, the company is poised for exponential growth in the rapidly expanding regenerative medicine sector.<\/p>\n

\nAbout<\/b> Integrant<\/b><\/p>\n

\nIntegrant is an Australian biotechnology company specialising in the integration of regenerative medicine and orthopaedic surgical products. Dedicated to AI-powered solutions for musculoskeletal repair, Integrant delivers premium, clinically advanced therapies from its Sydney base.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:<\/b>
Adelaide Slater
\n
Integrant Pty Ltd
\n
Phone: +61 439 880 233
\n
Email: media@integrant.com.au<\/a>
Website: www.integrant.com.au<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SYDNEY–(BUSINESS WIRE)–#ArtificialIntelligence–Integrant, a pioneering Australian biotechnology company, proudly announced today that it has officially been granted the Nasdaq ticker symbol **INGT**. This milestone facilitates the company\u2019s highly anticipated Initial Public Offering (IPO) on the Nasdaq Stock Market, positioning Integrant as a global leader in AI-enhanced regenerative medicine. Established in Sydney, Integrant specialises in the seamless … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62948","6":"format-standard","7":"category-industry"},"yoast_head":"\nIntegrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Integrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SYDNEY–(BUSINESS WIRE)–#ArtificialIntelligence–Integrant, a pioneering Australian biotechnology company, proudly announced today that it has officially been granted the Nasdaq ticker symbol **INGT**. This milestone facilitates the company\u2019s highly anticipated Initial Public Offering (IPO) on the Nasdaq Stock Market, positioning Integrant as a global leader in AI-enhanced regenerative medicine. Established in Sydney, Integrant specialises in the seamless ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T08:02:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260414004727\/en\/2774999\/22\/Integrant_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Integrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO\",\"datePublished\":\"2026-04-16T08:02:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/\"},\"wordCount\":371,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260414004727\\\/en\\\/2774999\\\/22\\\/Integrant_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/\",\"name\":\"Integrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260414004727\\\/en\\\/2774999\\\/22\\\/Integrant_Logo.jpg\",\"datePublished\":\"2026-04-16T08:02:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260414004727\\\/en\\\/2774999\\\/22\\\/Integrant_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260414004727\\\/en\\\/2774999\\\/22\\\/Integrant_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Integrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Integrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/","og_locale":"en_US","og_type":"article","og_title":"Integrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO - Pharma Trend","og_description":"SYDNEY–(BUSINESS WIRE)–#ArtificialIntelligence–Integrant, a pioneering Australian biotechnology company, proudly announced today that it has officially been granted the Nasdaq ticker symbol **INGT**. This milestone facilitates the company\u2019s highly anticipated Initial Public Offering (IPO) on the Nasdaq Stock Market, positioning Integrant as a global leader in AI-enhanced regenerative medicine. Established in Sydney, Integrant specialises in the seamless ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/","og_site_name":"Pharma Trend","article_published_time":"2026-04-16T08:02:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260414004727\/en\/2774999\/22\/Integrant_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Integrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO","datePublished":"2026-04-16T08:02:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/"},"wordCount":371,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260414004727\/en\/2774999\/22\/Integrant_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/","url":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/","name":"Integrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260414004727\/en\/2774999\/22\/Integrant_Logo.jpg","datePublished":"2026-04-16T08:02:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260414004727\/en\/2774999\/22\/Integrant_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260414004727\/en\/2774999\/22\/Integrant_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/integrant-awarded-nasdaq-ticker-ingt-ahead-of-highly-anticipated-ipo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Integrant Awarded Nasdaq Ticker \u201cINGT\u201d Ahead of Highly Anticipated IPO"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62948"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62948\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}